arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Axsome Therapeutics, Inc.

AXSM
$212.68 ▲ +2.36 (+1.12%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axsome Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.9B
Dividend Yield
Revenue Growth 57.4%
Op. Margin -33.1%
ROIC -36.7%
FCF / Share $-0.41
Trailing P/E
Price / Book 200.3x
FCF Yield
Debt / Equity 2.16
info Valuation on last close. End-of-day price, Aug 7, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$191.20M
↑ +57.4%
Net Income Profit after all expenses
$-64.54M
↓ -8.6%
Operating Margin Operating profit as % of sales
-33.1%
↓ -140.9% 9th
FCF / Share Free cash flow per share
$-0.41
↑ +54.5%
Long-Term Debt Long-term obligations
$117.85M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
2
Financial Health
25
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters